Fortress Biotech (NASDAQ:FBIO) Releases Earnings Results, Beats Estimates By $0.53 EPS

Fortress Biotech (NASDAQ:FBIO) announced its earnings results on Monday. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.53, Zacks reports.

Fortress Biotech Stock Performance

Shares of NASDAQ FBIO traded down $0.05 during trading on Monday, reaching $1.56. The company had a trading volume of 319,235 shares, compared to its average volume of 408,431. Fortress Biotech has a 52 week low of $1.36 and a 52 week high of $2.89. The business’s 50 day moving average price is $1.71 and its 200-day moving average price is $1.78. The stock has a market cap of $43.06 million, a PE ratio of -0.51 and a beta of 1.75.

Analyst Upgrades and Downgrades

Separately, Roth Mkm reiterated a “buy” rating and issued a $16.00 price objective (up previously from $15.00) on shares of Fortress Biotech in a research report on Tuesday, March 11th.

Fortress Biotech Company Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.